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Thank you again for submitting your manuscript on allosteric E2-E3 interactions for consideration by The EMBO Journal. We have now received the comments from three referees, and I am pleased to inform you that all of them find this work interesting and are supportive of its publication, pending adequate revision of a limited number of specific points, as listed below. We shall therefore be happy to consider this work further, and I would at this stage like to invite you to revise the manuscript according to the referees' suggestions.
When preparing your letter of response, please be reminded that our policy to allow only a single round of major revision will necessitate diligent and comprehensive answering, and also bear in mind that this letter will form part of the Peer Review Process File available online to our readers in the case of publication. Please also note that during our standard three months revision time, any competing manuscripts published here or elsewhere will have no negative impact on our final assessment of your revised study. Should you have any additional questions regarding this revision, please do not hesitate to contact me.
Thank you for the opportunity to consider this work for publication! I look forward to your revision.
_____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
Das, Byrd, Weissman and colleagues have previously shown that G2BR binds to the backside of Ube2g2 and allosterically improves Ube2g2's binding affinity for gp78 RING domain. This was elegantly illustrated by using a G2BR peptide in trans. How G2BR improves Ube2g2's binding affinity for gp78 RING domain remains elusive. In this manuscript, Das et al. dissected the allosteric regulation between G2BR, Ube2g2 and gp78 RING domain. Data include comprehensive NMR data on various combinations of G2BR/Ube2g2/Ube2g2~Ub/gp78 RING complexes, X-ray crystal structure and NMR model of G2BR-Ube2g2-gp78 RING complex, NMR and ITC binding analyses of various complexes/mutants and ubiquitination assays. Collectively, the data showed that G2BR binding induces conformational changes in Ube2g2's 4 2 loop making E108 (located on this loop) more favorable to interact with gp78 RING's R379. This interaction is required for G2BR-induced allosteric E2-RING interaction. Interestingly, upon RING binding to Ube2g2, the RING domain induces a reverse allostery by reducing G2BR binding. RING's W345 induces a slight conformational change in Ube2g2's 1 helix thereby reducing several G2BR-Ube2g2 contacts. They showed that this feedback allosteric effect is crucial for Ube2g2 release from gp78 and recharging by E1 to ensure processive ubiquitination.
The results are interesting and provide molecular insights into allosteric regulation of E2-E3 complex. The data are convincing and high quality. This work will be of interest to scientists working in the ubiquitin field and allosteric regulation of proteins/enzymes.
Minor comments
1. Another Ube2g2-G2BR peptide complex (PDB 3FSH) has been reported. In particular, Ube2g2's 4 2 loop conformation did not undergo significant conformational change upon binding to G2BR and is within the apo Ube2g2 conformation. Comparison of Ube2g2 structures and G2BR-induced 4 2 loop conformational change need to be placed in the light of this structure. The authors should include their NMR CSP data on Ube2g2 upon G2BR binding to strengthen their discussion on the 4 2 loop conformational change.
2. The NMR data in Figure 4D and E are a bit difficult to follow. The authors need to explain clearly how they determine the absolute difference of the CSP. For example, in the Ube2g2~Ub:G2BR complex ( Figure 4D ), there are CSP contributions from Ube2g2-Ub ( Figure 4A ) and Ube2g2-G2BR interactions. Subtraction of CSP from Ube2g2:G2BR complex should yield CSP from Ube2g2-Ub interactions. It seems that the authors may have included CSP from Ube2g2~Ub in their calculation to obtain the difference. This needs to be explained in the Figure legend. Also the authors should mention how significant CSP cut-offs are chosen.
3. Page 17 "E1:E2~Ub complex from ..." The authors have used ~ to denote for thioester or covalent linkage between E2 and Ub. The Ub in this E1-E2 complex is bound non-covalently, it would be more appropriate to use : to describe this complex.
4. Page 19 "and RING induces allosteric feedback to ensure E3 release and a ...". Not sure if the authors mean E2 release.
5. The author should include the linker sequence used to fuse RING and G2BR in the method section.
6. In Table 1 , Complex 19 should be Ube2g2 E108R: G2BR.
Referee #2 (Remarks to the Author):
Byrd and colleagues present structural and biochemical characterization of an unusual RING-type E3 ubiquitin ligase, gp78, and its cognate E2 ubiquitin-conjugating enzyme, Ubeg2g. There are several novel and intriguing findings in the paper that will be of interest to the general protein ubiquitination field. gp78 is one of a small number of IRNG-type E3s known to carry an additional non-RING E2-binding domain. Previous studies had demonstrated that the so-called "G2BR" binds the backside of the E2 and results in remarkably high affinity between the E3 and E2. This result presented a paradox, however, as it is presumed that more modest binding affinity is required to ensure that a discharged E2 will dissociate from the E3. If it does not, it essentially becomes product inhibition. Despite the high affinities, the measured off-rates are also fairly fast and are within the expected time regime for the system to work. Second the authors use both NMR and crystallography to define the structure of the gp78 RING-G2BR/Ube2g2 complex. The structure reveals an interesting variation on the recently described "theme" of allosteric activation of E2s via a conserved E3-E2 H-bond network. An E3 Arg side chain analogous to the one seen in other RING/E2 structures is involved, but instead of contacting the E2 backbone it makes a salt bridge with a Glu in the E2 loop. The paper goes on to present a clear and thorough characterization of this interaction and its functional ramifications. Third, the authors document a novel and unexpected "reverse allostery" that allows E2 exchange on and off gp78. Overall, the experiments are thorough and well executed and the authors' conclusions are well supported by their results. They present a wellsupported model that will likely serve as the archetype for other E2/E3 systems. The manuscript is acceptable as is, although I do have a few quibbles and minor suggestions to enhance its readability and impact, outlined below.
1. The authors' use of the parameter they call "allostery" is not particularly intuitive nor is it very informative (at least to this reader.) A calculation in terms of G or free energy coupling in the presence and absence of the G2BR could be an additional field in Table 1. 2. Although I have no argument with the authors' choice to mutate the E2 residue E108 to Ala and Lys, it would have been nice to see what happens if Gln is substituted given that this is the residue in the UbcH5 structures. If the authors have the data, they should be encouraged to include it, but it's not necessary for them to do new experiments if they have not made this mutant. It's more a curiosity than a necessity.
3. Regardless of whether the authors include the additional mutant at the E108 position, they may wish to consider expanding their discussion of the interaction involving this position, which uses the side chain in Ube2g2 but the backbone in UbcH5. The position is not particularly well conserved, but do the authors predict that other E2s will use the side chain-to-side chain strategy? 4. As no error estimates are provided for the Kd values obtained from the SPR data, I think that suggesting the 1 micromolar and 3 micromolar are different is a stretch. On the other hand, the values for the off-rates from the same experiments are more reliable as these rates do not depend on protein concentrations. 5. In the Summary, it is stated that the secondary binding site in gp78 is "unique." There are other E3s that have non-RING binding regions, so gp78 is not one-of-a-kind in this respect.
Referee #3 (Remarks to the Author):
In this manuscript a combination of structural, biophysical and biochemical approaches is employed to study how the cognate E2/E3 pair Ube2g2 and gp78 interact, in particular how the two components of the interaction influence each other. Previously it was shown that gp78 uses a G2BR domain to interact with the backside of the E2, besides the canonical RING interaction. Here these domains have been fused to each other, showing that both interfaces change due to the presence of the other, with increased binding to the RING domain and a decreased interaction to G2BR, allowing the reaction to proceed.
The first interface is validated by a charge-swap mutant that restores loss of binding and allostery. However, it only marginally restores activity, since this region is additionally important for stabilization of ubiquitin (via Q40) in the reaction. The reverse allostery from the RING binding to the G2BR is interesting: it explains the lack of additivity between the two binding interfaces and also how the reaction can progress despite the high affinity for G2BR. Interestingly, the lack of this reverse allostery in the 'feedback-off' mutant W345ER379E affects the loading rate negatively, showing how this feedback is important for E2 exchange and hence for cycling of the reaction. This combination of interactions is novel and interesting. The paper is well-written and the data are convincing and clearly presented.
Minor point: -A number of experiments are mentioned, but not shown: either show the data or remove the statement 1st Revision -authors' response 06 July 2013
We thank the reviewers for the careful review and constructive comments regarding this study. The corrections suggested by the reviewers have improved the manuscript, and we hope that the revised manuscript will be acceptable for publication in the EMBO journal.
Reviewer 1 minor comments 1. Another Ube2g2-G2BR peptide complex (PDB 3FSH) has been reported. In particular, Ube2g2's β4α2 loop conformation did not undergo significant conformational change upon binding to G2BR and is within the apo Ube2g2 conformation. Comparison of Ube2g2 structures and G2BR-induced β4a2 loop conformational change need to be placed in the light of this structure. The authors should include their NMR CSP data on Ube2g2 upon G2BR binding to strengthen their discussion on the β4α2 loop conformational change. 2. The NMR data in Figure 4D and E are a bit difficult to follow. The authors need to explain clearly how they determine the absolute difference of the CSP. For example, in the Ube2g2~Ub:G2BR complex ( Figure 4D ), there are CSP contributions from Ube2g2-Ub ( Figure 4A ) and Ube2g2-G2BR interactions. Figure 4 caption has been expanded to explain this point.
The cut-offs in figure 4A and 4B were chosen as twice the standard deviation (as suggested by Mike P. Williamson, Progress in Nucl Mag. Reson. Spect. 2013, 73, 1-16 
